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selected rings endothelium was rubbed. Rings were mounted in an organ bath chamber 
and prewntracted with potassium chloride. Responses of prawntraded IMA rings to 
increasing dose of sertraline (lo’-1OsMol.L~‘) were compared with vehicle. Relaxations 
were expressed as a percentage of precontraction. 
Secondly, we assessed dose-response curves of phenylephrine (10.‘-1O~sMol.L”) in the 
absence or presence of serlraline (105Mol.L~>. 
Results: Sertraline induced concentration-dependent vasodllation (p<O.Ol; repeated 
measures ANOVA combined with post-hoc t-statistics), which was profound in nature 
(maximal dilatory effects exceeding 100% in the concentration-range used). There were 
no significant differences between rubbed and unrubbed rings,, thus vasodilation was 
independent of the endothelium. Presence of sertraline markedly attenuated contractile 
responses to phenylephrine. resulting in a significant rightward shift of the concentration- 
response curve (~~0.05). 
Conclusion: Our results suggest that sertraline may be protective against arterial vasos- 
pasm in depressive post-CABG patients. Vasodilatory properties of sertraline may have 
important clinical implications in the use of SSRls. 
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1203-l 23 Hypertension Adverse Experiences Among 
Osteoarthritis Patients Treated With Rofecoxib, 
Celecoxib, or Acetaminophen in the VACT Trials 
Greoow P. Geba, Adam 8. Polis, Richard A. Petruschke, William F. Keane, Merck 8. Co., 
Inc., West Point, PA 
Background: Inhibition of cyclooxygenase (COX)-2 may alter renal function in some 
patients due to effects on renal blood flow and tubular function. We evaluated hyperten- 
sion adverse experiences (AEs) in patients treated with the COX-2 specific inhibitors, 
rofecoxib and celecoxib compared to acetaminophen. Melhods: A total of 1960 patients 
(VACT 1, N=381 and VACT 2. N=l579) with osteoarthritis of the knee were enrolled in 
two randomized. double-blind, active comparator efficacy trials. The patients received 
treatment with rofecoxib 12.5 mg (N=355) or 25 mg (N=622). celecoxib 200 mg (N=620), 
or acetaminophen 4000 mg (N=363) daily for 6 weeks. Patient demographics were simi- 
lar across treatment groups in both studies. The majority of patients were Cauoaslan 
(87%), women (68%), with a median age of 62 years. An exploratory analysis was per- 
formed to evaluate the percentage of patients with hypertension-related AEs and dlscon- 
tinuations due to hypertension-related AEs. Hypertension-related AEs were dominated 
by the term hypertension, but included all terms that implied hypertension. Results: 
Overall, 38 (1.9%) patients experienced an hypertension-related AE. The percentage of 
patients by treatment group was rofecoxib 12.5 mg, 2.8% (10 patients); rofecoxib 25 mg, 
1.3% (8 patients); celecoxib 200 mg, 1.8% (11 patients); and acetaminophen 4000 mg, 
2.5% (9 patients). The percentage for all rofecoxib patients was 1.8%. Less than 1% of 
the patients in each treatment group discontinued the studies due to a hypertension- 
related AE. No clinically meaningful difference in mean change from baseline in blood 
pressure was observed when comparing rofecoxlb at both doses to celecoxib 01 acetami- 
nophen. Conclusion: The percentage of patients with hypertension-related AEs was 
small. Although not a prespeclfied analysis, we observed comparable incidence of hyper- 
tension-related AEs comparing rofecoxlb and celecoxib. Patients treated with COX-2 
inhibitors were at no greater risk to experience a hypertension-related AE than those 
treated with acetaminophen. 
1203-124 Prevention of Renal Fibrosis With Dual ACE+NEP 
Inhibition With MDL 100,240 in a Transgenic Model of 
Angiotensin II-Dependent Hypertension 
Valeria Valdisolo, Anna Sandra Belloni. Diego Guidolin, Achille Cesare Pessina, Gian 
Paolo Rossi, Clin Med 4, Padova, Italy, University of Padua, Padova, Italy 
BACKGROUND. Dual ACE+NEP inhibition is being proposed as a novel therapeutic 
strategy in cardiovascular disease. As NEP is involved in the degradation of vasodllatory 
and growth-inhibitory peptides, like ANP. BNP, adrenomedullin and bradykinin, and is 
mainly expressed in the kidney epithelial brush border, dual ACE+NEP Inhibition might 
have peculiar nephroprotective effects. 
METHODS. To verify this hypothesis we randomly allocated male heterozygous RenP 
transgemc rat (TGR(Ren2)27), a model of prominent cardiovascular disease, to receive a 
placebo, MDL 100,240 (40 mg/Kg ) or ramipril(5 mg/Kg ) by gavage for 8 weeks. After 4 
week the bradykinin 4 receptor antagonist icatibant (0.5 mg/Kg) was administered 
(osmotic minipumps) to 50% of rats receiving MDL 100,240 or ramipril. At the end of 
treatment, glomerular density (GD), volume (GV), fibrosis (GF) and tubulointerstitial fibro- 
sis (TF) were measured by PC-assisted histomorphometry on Masson’s trichrome- and 
Sirius Red- stained cryosections with a specific software (Leica QwinTM). 
RESULTS. Compared with placebo, MDL 100,240 decreased blood pressure (from 
251+24 to 137t6 mmHg, pO.001) being as effective as ramipril (127r4). TF was signifi- 
cantly reduced (from 13tl% in placebo, m * SEM) in MDL 100,240 (to 9*1%, p=O.O03) 
and in ramipril (to 9+1%. p=O.O03) treated rats. At variance, GD, GV and GF were not 
affected. lcatibant significantly (p=O.OOl) blunted the lowenng of TF in both MDL 100,240 
(13*1%) and ramipril (13+1%) treated rats. 
CONCLUSION. 1) Enhancement of bradykinin. via 8, receptor, plays a relevant role In 
the nephroprotective effects of both MDL 100,240 and tamipril; 2) TF appear to preced 
GF. GD and GV and therefore may be an accurate index for estimating early renal dam- 
age in TGR(Ren2)27. 
1203-l 25 Effects of Valsartan and Valery1 4-Hydroxy Valsarlan on 
Human Platelets: A Possible Missing Link to Explain 
Reduction of Acute Vascular Events With Angiotensin II 
Receptor Blockers 
Victor L. Serebruany, Alex I. Malinin. David R. Lowry, David C. Sane, Randy L. Webb, 
Sidney 0. Gonlieb. Charles H. Hennekens, Sinai Hospital, Johns Hopkins University, 
Baltimore, MD, University of Miami, Miami, FL 
Background: Valsartan (V) selectively blocks angiotensin II binding to the AT, receptor. 
Since platelet activation plays a key role in the pathogenesis of coronary and cerebrovas- 
cular occlusion, and since AT, receptors are present on the platelet surface, we 
assessed the in vitro effects of V and its metabolite, valeryl 4.hydroxy valsartan (V4HV), 
on platelets in 20 subjects with multiple vascular disease risk factors. Methods: Platelet 
characteristics in blood samples pretreated and incubated with 10 nmol to 100 wmol con- 
centrations of V and V4HV were assessed by conventional and whole blood aggregome- 
try. Closure time, platelet activation units, platelet-bound fibrinogen, and platelet- 
leukocyte formation also were measured, as well as expression of platelet receptors 
using several monoclonal antibodies. Results: Pretreatment of blood with V and V4HV 
resulted in inhibition of conventional (ADP: k.0002, V; epinephrine: f=.OOOl, V4HV) 
and collagen-induced (E.02, V; P=.OOOi, V4HV) platelet aggregation. Expression of 
many monoclonal antibodies and platelet-bound fibrinogen was significantly reduced 
compared with autologous baseline activity. Closure time was delayed (E.02, V; e.03, 
4VHV), indicating platelet inhibition in whole blood under high shear conditions. Intensity 
of platelet-leukocyte formation and platelet activation remained unchanged. Platelet inhi- 
bition was not dose-dependent and was more potent for 4VHV than V in the therapeutic 
range. Conclusions: Valsartan and 4VHV exhibited significant in vitro inhibition of 
human platelets. Their antiplatelet properties appear to be independent of those of other 
antiplatelet agents. Whether valsartan reduces vascular ischemic events via additional 
pathways of platelet inhibition in patients with myocardlal infarction and ischemic stroke 
reqwes further research. 
1203-126 The Relationship Between Angiotensin Converting 
Enzyme Gene Polymorphism and Hypertensive 
Retinopathy 
Nezihi Baris, Ozer Badak, Ozgur Aslan. Onder Kirimli, Ozhan Goldeli, Bahri Akdeniz, 
Sema Guneri, Dokuz Eylul University, Izmir. Turkey 
Background: Retlnopathy is the important complication and major target organ damage 
of hypertension. We aimed to investigate the relationship between angiotensin convert- 
ing enzyme (ACE) gene polymorphism and hypertensive retmopathy. 
Methods: Fifty-one patients (31 female, mean age:53,3 r 9 years) with essential hyper- 
tension were enrolled in this study. Patients with diabetes mellitus were excluded. Hyper- 
tensive retinopathy was diagnosed in dark room with direct ophtalmoscopy by an 
ophtalmalogist blinded to climcal data. Polymerase chain reaction was used to detect the 
insertion/deletion (l/D) polymorphism of the ACE gene. Statistical analysis was per- 
formed using the chi-square and analysis of variance methods. 
Results: Basal characteristics of the patients were similar in groups. The significant dif- 
ferences were found among these groups.(Table) 
Table 
ACE Genotype 
Retinopathy DD (n=20) DI (w24) II (n=7) P 
Yes 20 (%lOO) 14 (%60,9) 2 (%28,6) <0,0001 
No 0 (%O) 9 (%39.1) 5 (%71,4) <0,0001 
Conclusion: Hypertensive patients with D allel of ACE gene represent a tendency to 
hypertensive retinopathy. Identification of ACE genotype in hypetlensive patients might 
be useful to discriminate the patients who are more susceptible to hypertensive retinopa- 
thy 
1203-l 29 Safety of the Centrally Acting Wake-Promoting Agent 
Modafinil in Hypertensive Sleep Apnea Patients 
Jonathan Sackner-Bernstein, S. Arora, Craig Q. Earl, St. Luke’s_Roosevelt Hospital 
Center, New York, NY, Cephalon Inc., West Chester, PA 
Background. Obstructive sleep apnea (OSA) IS common in patients with cardiovascular 
disease and contributes to hypertension (HTN) and sympathetic nervous system activa- 
tion. The centrally-acting wake-promoting agent modafinil reduces excessive daytime 
sleepiness (EDS) and improves quality of life (QOL) when used adjunctively in OSA. 
Because of theoretical risk of CNS stimulants in cardiovascular disease, we evaluated 
the cardiovascular effects of modafinil in OSA patients with current or past history of 
HTN. 
Methoda Effects on heart rate (HR) and systolic and diastolic blood pressure (BP) mea- 
sured at rest and clinical experiences during therapy were determined from 3 random- 
ized, double blind, placebo-controlled trials of modafinil for OSA (2-l 2 weeks of therapy 
with placebo, 200 or 400 mg qd, n=218. 109, 214 respectively). HTN was defined by cur- 
rent therapy or the diagnosis of HTN currently or in the past. 
Reeulta 274 HTN patients were middle aged (52 yrs) obese (BMl=36.3) Caucasian 
(87%) men (79%) with BP of 130/81. In HTN group, modafinil did not increase BP 01 HR, 
nor were there differences in clinical cardiovascular adverse effects. Combining HTN 
with non-HTN revealed similar lack of effect on BP and HR by modafinil 200 mg or 400 
